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Nolatrexed dihydrochloride (AG337, ThymitaqTM) was designed
by Agouron Pharmaceuticals, La Jolla, CA, USA using knowledge
of the three-dimensional structure of the active site of thymidylate
synthase (TS) (Webber et al, 1993). It acts at the folate-binding site
of the TS enzyme and, as a non-classical antifolate, the activity of
nolatrexed is not dependent on activation by the enzyme folyl
polyglutamate synthetase (FPGS) or a specific transport mecha-
nism for cellular uptake. Previous studies with nolatrexed have
shown that the optimal schedule of administration is as a contin-
uous intravenous infusion over 5 days at a dose of 800 mg m–2
day–1 (Rafi et al, 1995, 1998). Clinical activity has been demon-
strated in head and neck cancer (Belani et al, 1997a), hepatoma
(Stuart et al, 1996), pancreatic carcinoma (Loh et al, 1997) and
colonic carcinoma (Belani et al, 1997b). The main toxicities asso-
ciated with nolatrexed are haematological and gastrointestinal
(Rafi et al, 1998).
Paclitaxel, derived from the Pacific yew tree Taxus brevifolia,
acts by stabilizing microtubules against depolymerization.
Paclitaxel has demonstrated anti-tumour activity against a wide
variety of different tumour types, most impressively ovarian
(Goldspiel, 1997) and breast carcinoma (D’Andrea and Seidman,
1997; Goldspiel, 1997; Wilson et al, 1994). However, it has also
shown significant activity against squamous cell carcinoma of the
head and neck (Aisner and Cortes-Funes, 1997; Vokes et al, 1995).
Major paclitaxel side-effects include myelosuppression, total
alopecia and paraesthesiae (Rowinsky, 1997).
In view of the activity of both nolatrexed and paclitaxel in head
and neck cancer and, with the exception of myelosuppression,
their non-overlapping toxicities, the combination of the two drugs
has been explored in clinical and laboratory-based studies. As the
schedule of administration of a combination of drugs can play a
major role in the toxicity and activity, three different schedules of
drug administration were explored. On schedule 1, paclitaxel was
administered prior to nolatrexed and on schedule 3 the order was
reversed. On schedule 2, the paclitaxel was administered in the
middle of the nolatrexed infusion. The pharmacokinetic results
obtained for the patients on schedule 2 were of particular interest
given that both paclitaxel and nolatrexed undergo metabolism
mediated by the cytochrome P450 system.
The aims of the clinical study were:
1. To determine whether nolatrexed and paclitaxel could be
safely given in combination
2. To assess the toxicity of the combination and to record any
anti-tumour activity
3. To optimize the schedule of administration of the two agents
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Summary A clinical study of nolatrexed dihydrochloride (AG337, ThymitaqTM) in combination with paclitaxel was performed. The aims were
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administration of the two drugs: (1) paclitaxel 0–3 h, nolatrexed 24–144 h; (2) nolatrexed 0–120 h, paclitaxel 48–51 h; (3) nolatrexed 0–120 h,
paclitaxel 126–129 h. Paclitaxel was administered at a dose of 80 mg m–2 over 3 h and nolatrexed at a dose of 500 mg m–2 day–1 as a 120-h
continuous intravenous infusion. Plasma concentrations of both drugs were determined by high performance liquid chromatography. In vitro
growth inhibition studies using corresponding schedules were performed using two head and neck cancer cell lines. In both HNX14C and
HNX22B cell lines, synergistic growth inhibition was observed on schedule 2, whereas schedules 1 and 3 demonstrated antagonistic effects.
In the clinical study, there was no effect of schedule on the pharmacokinetics of nolatrexed. However, patients on schedules 1 and 3 had a
higher clearance of paclitaxel (322–520 ml min–1 m–2) than those on schedule 2 (165–238 ml min–1 m–2). Peak plasma concentrations
(1.66–1.93 vs 0.86–1.32 mM) and areas under the curve (392–565 vs 180–291 mM min–1) of paclitaxel were correspondingly higher on
schedule 2. The pharmacokinetic interaction was confirmed by studies with human liver microsomes, nolatrexed being an inhibitor of the
major routes of metabolism of paclitaxel. Toxicity was not schedule-dependent. Nolatrexed and paclitaxel may be safely given together when
administered sequentially at the doses used in this study. Studies in vitro suggest some synergy, however, due to a pharmacokinetic
interaction, paclitaxel doses should be reduced when administered during nolatrexed infusion. © 2000 Cancer Research Campaign
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between the two drugs.
In vitro studies were performed using two head and neck cancer
cell lines and human liver microsomes to investigate the growth
inhibitory effects and possible interactions for the same schedules
of drug administration as used in the clinical study.
MATERIALS AND METHODS
Materials
Nolatrexed and associated materials were obtained as described
previously (Rafi et al, 1995). Paclitaxel was kindly supplied by
Bristol Myers Squibb (Princeton, NJ, USA).
For the tissue culture work, RPMI-1640 medium complete and
trypsin were supplied by Gibco-BRL, Life Technologies (Paisley,
UK) and fetal calf serum by Globe Pharmaceuticals (Surrey, UK).
EDTA, trichloroacetic acid, TRIS base, sulphorhodamine B and
dimethyl sulphoxide (DMSO) were all obtained from Sigma
Chemical Company (Poole, Dorset, UK). Glacial acetic acid and
dialysis membrane was supplied by BDH (Dorset, UK). Life
Technologies (Paisley, UK) also supplied the NUNC 96-well
plates which were read on a Dynatech MR7000 microtitre plate
reader (Dynatech, Guernsey, UK). The two head and neck cancer
cell lines, HNX14C and HNX22B, were kindly provided by Dr
Braakhuis (Free University, Amsterdam, The Netherlands).
In vitro combination studies
The two head and neck cell lines, HNX14C and HNX22B, were
cultured at 37°C in a humidified atmosphere of 95% air/5% carbon
dioxide in RPMI-1640 medium containing 10% v/v dialysed fetal
calf serum, supplemented with glutamine and sodium bicarbonate.
Both cell lines were passaged twice weekly using trypsin–EDTA.
Initial studies were performed to determine the IC50 for nolatrexed
(120-h exposure) and paclitaxel (3-h exposure) for each cell
line. For each experiment, exponentially growing cells were
washed, trypsinized and seeded at a concentration of 5 ´ 103 ml–1
(HNX14C) or 1 ´ 104 ml–1 (HNX22B) into the wells of a 96-well
plate. Cells were then left to adhere for 24 h before drug treat-
ment. For each cell line, 3 different schedules of drug combina-
tion, corresponding to those used in the clinical study, were
studied.
Schedule 1: paclitaxel 0–3 h, nolatrexed 24–144 h
After the initial 24 h, cells were exposed to varying concentrations
of paclitaxel for 3 h. The drug was removed and the plates were
then left for 21 h, after which varying concentrations of nolatrexed
were added. The paclitaxel and nolatrexed drug concentrations
used were as follows: 0.01 ´ IC50 for the drug as a single agent,
0.1 ´ IC50, 0.3 ´ IC50, IC50, 3 ´ IC50, 10 ´ IC50. The ratio of drug
concentrations at each dose was therefore the same. Cell growth
inhibition was then assessed at 6 days (144 h) by the sulphor-
hodamine B (SRB) assay (Skehan et al, 1990). For each cell line,
experiments were repeated on a minimum of three occasions.
Schedule 2: nolatrexed 0–120 h, paclitaxel 48–51 h
Cells were seeded as above and identical nolatrexed concentra-
tions as those used in schedule 1 were added 24 h after cell adher-
ence. At 48 h, the nolatrexed was removed and replaced by a
combination of both nolatrexed and paclitaxel. This was replaced
with nolatrexed alone 3 h later. Duplicate plates were used for this
schedule and SRB assays were performed at day 6 (144 h) and day
8 (192 h). Experiments were repeated at least three times.
Schedule 3: nolatrexed 0–120 h, paclitaxel 126–129 h
Triplicate plates were set up and cells were exposed to nolatrexed
for 120 h. The nolatrexed was then removed and replaced by pacli-
taxel 6 h later. At 129 h, the paclitaxel was removed. SRB assays
were performed on days 6, 8 and 10 (144, 192 and 240 h).
Experiments were repeated at least three times.
On every 96-well plate for each schedule, control columns of
cells were exposed to medium alone, medium/DMSO (the pacli-
taxel was diluted in DMSO) and single-agent drug IC50 concentra-
tions.
The effects of the drug combinations were evaluated using the
method of Chou and Talalay (1984). For each schedule of drug
administration for both cell lines, curves were plotted of the log of
the combination index (CI) versus the fraction of cells affected
(Fa).
Patient population
In total, nine patients were available for study, three on each of the
3 schedules of drug administration. Individual patient characteris-
tics are shown in Table 1. Eight of the patients were female, age
ranged from 40 to 72 years, and a number of different tumour
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Table 1 Patient characteristics and outcome
Patient no. Age Sex Diagnosis Schedule Prior chemo regimes No. of courses Response
3 52 F Adrenocortical 1 3 6 SD
6 47 F Colorectal 1 2 1 PD
9 65 F Melanoma 1 None 4 SD
5 45 F NSCLC 2 1 4 SD
7 40 F *Adenocarcinoma 2 None 2 PD
10 72 M Caecal 2 1 1 NE
2 59 F Ovarian 3 2 1 NE
4 56 F Ovarian 3 3 2 PD
8 44 F Breast 3 1 1 NE
Patient 1 never commenced treatment due to deteriorating clinical condition. NSCLC = non-small-cell lung cancer. * = unknown primary site. SD = stable
disease, PD = progressive disease, NE = not evaluable for response.types were treated. Only two of the nine patients were
chemotherapy naive. Twenty-two courses of treatment were
administered in total. The study was approved by the Regional
Ethical Committee. All patients gave written informed consent
prior to registration on the study. Study exclusion and inclusion
criteria were as described previously (Rafi et al, 1995), with the
additional exclusion of patients having previously been treated
with paclitaxel or nolatrexed. Although ultimately intended for 
use in patients with head and neck cancer, this initial study was
performed in any patient with a solid tumour that was not
amenable to conventional therapy.
Patient monitoring
Before treatment, a complete history was taken and a physical
examination with evaluation of WHO performance status
performed. A full blood count, urea and electrolyte concentrations
and liver function tests were measured and, in addition, an electro-
cardiogram (ECG) and EDTA clearance determination were
obtained. All but the latter two tests were repeated twice weekly
during the first course of treatment and weekly thereafter.
Although the primary purpose of the study was not to assess
tumour response, patients with measurable or evaluable disease
had representative lesions assessed at least every two courses by
physical examination or appropriate radiological studies.
Treatment courses were repeated every 3 or 4 weeks depending on
recovery of the patient from the previous course. Treatment was
continued to a maximum six courses. Patients were withdrawn
from the study in the event of progressive disease, or if it was felt
by the investigator to be in the best interest of the patient. Common
toxicity criteria (CTC) for toxicity and response were used.
Clinical and drug metabolism studies
Nine patients were randomized to one of three different schedules
of administration of nolatrexed and paclitaxel:
Schedule 1: paclitaxel 0–3 h, nolatrexed 24–144 h
Schedule 2: nolatrexed 0–120 h, paclitaxel 48–51 h
Schedule 3: nolatrexed 0–120 h, paclitaxel 126–129 h.
Three patients were treated on each schedule.
Nolatrexed was administered as a continuous 120-h intravenous
infusion via a central venous catheter at a dose of 500 mg m–2
day–1. The total dose was diluted in normal saline and slowly
administered over the 5-day period using a Baxter pump (Baxter
Healthcare, Newbury, Berks, UK). Paclitaxel was prepared
according to the instructions of the manufacturer and administered
as a 3-h intravenous infusion in 5% w/v dextrose at a dose of 
80 mg m–2. In order to prevent hypersensitivity reactions to the
paclitaxel, patients were pre-medicated with dexamethasone,
chlorpheniramine and cimetidine. Courses of treatment were
repeated every 3–4 weeks depending on the recovery of the patient
from the prior course.
Pharmacokinetic sampling was performed during the first
course of treatment in all nine patients. The timing of samples was
designed such that data from different schedules were comparable.
Plasma samples were stored at –20°C until analysis by methods
described previously (Rafi et al, 1995; Siddiqui et al, 1997).
In vitro studies investigating the effect of nolatrexed on the
metabolism of paclitaxel were conducted using human liver micro-
somes (Keystone Skin Bank Exton, PA, USA). Ten individual
human liver microsome preparations with P450 content (deter-
mined by CO difference spectra) greater than 0.3 nmol mg–1 were
pooled together based on equivalent milligrams of protein (deter-
mined by the Pierce Kit, Pierce Rockford, IL, USA). This pooling
method ensured that there was equal contribution of the
cytochrome P450 isoforms from each liver since the protein
concentrations from each sample varied from 11.6 to 28.3 mg ml–1.
Pooled human liver microsomes (1 mg protein per ml) were
incubated with paclitaxel (for preliminary study 40, 80 and 200 mM
and for Ki determination 2.5, 5, 20 mM) and nolatrexed (for prelim-
inary study 0–10 mM and for Ki determination 0–2.0 mM) in 
100 mM potassium phosphate buffer, pH 7.4, at 37°C in a shaking
water bath for 5 min before initiating the reaction with NADPH 
(2 mM final concentration). A control sample containing all
reagents except nolatrexed was also included. The final volume of
each incubation was 0.5 ml. The reaction was terminated after 20
min by the addition of acetonitrile (5 ml). Samples were vortexed
on a SP multi-tube vortexer (Baxter, McGraw Park, IL, USA) for
10 min, followed by centrifugation at 2000 g for 10 min at room
temperature. The organic layer was removed and evaporated under
a gentle stream of nitrogen using a Dri-Block sample concentrator
(Techne, Princeton, NJ, USA) at 50°C. Samples were reconstituted
in 200 ml in 60% acetonitrile/40% 10 mM ammonium phosphate
buffer, pH 4.0.
Paclitaxel and 6a-hydroxypaclitaxel were measured by a previ-
ously published method (Jamis-Dow et al, 1995). Testosterone
metabolism was monitored by high-performance liquid chro-
matography (HPLC), with UV detection at 254 nm (Lillibridge 
et al, 1998).
Pharmacokinetic parameters were estimated by non-compart-
mental analysis. Area under the concentration-time curve (AUC)
for plasma was calculated using a combination of trapezoid and
log-trapezoid methods. Half-life was calculated from the terminal,
log-linear portion of the plasma concentration–time curve.
RESULTS
In vitro combination cytotoxicity studies
From the single-agent in vitro studies performed, the following
IC50S were calculated (mean (s.d.) n = 3): 3-h paclitaxel exposure;
HNX14C 0.031 (±0.006) mM, HNX22B 0.038 (±0.005) mM; 120-h
nolatrexed exposure; HNX14C 1.12 (±0.06) mM, HNX22B 0.66
(±0.06) mM.
For schedule 1 the combination of paclitaxel and nolatrexed in
vitro demonstrated antagonistic effects for both cell lines, as
demonstrated in Figures 1 and 2. For HNX14C the pattern on
schedule 2 was different. When cell growth was measured on day
6 there was primarily antagonism, with some synergistic effects,
but only at high levels of growth inhibition (Figure 1A). However,
when growth was measured on day 8, there was marked synergism
throughout the range of Fa (Figure 1A). For the HNX22B cell line
treated with schedule 2, some synergism was again observed, but
only at values of Fa greater than 0.5 (Figure 2A). Indeed the
combination appeared to behave in an antagonistic manner below
this Fa value. With schedule 3 and for Fa values of less than 0.75
in the HNX22B cell line, antagonism was observed for the
HNX22B cell line regardless of the day on which cell growth was
determined (Figure 2B). Similarly, for schedule 3 in the HNX14C
cell line, the appearance of the CI/Fa graphs for growth inhibition
on days 6, 8 and 10 are almost identical and reveal antagonism up
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predominate (Figure 1B). In conclusion, the in vitro data showed
some evidence of synergy on schedule 2, particularly in the
HNX14C cells. However, the effect was not sufficiently consistent
to preclude clinical assessment of all three schedules.
Clinical study
Pharmacokinetics
Full pharmacokinetic sampling was performed on the first course
for each of nine patients. The pharmacokinetic parameters of
interest were peak plasma concentration, AUC, clearance and half-
life of both nolatrexed and paclitaxel. In addition, the peak
concentration and AUC of the two main paclitaxel metabolites
was measured, i.e. those caused by 6-hydroxylation and 3¢phenyl-
p-hydroxylation of the parent compound. Plasma concentration-
time curves of nolatrexed and paclitaxel for a typical patient
on each schedule are represented in Figure 3. The paclitaxel
pharmacokinetic data are shown in Table 2 with the corresponding
data for nolatrexed in Table 3.
Whilst nolatrexed pharmacokinetics were unaffected by
schedule, a schedule-dependent interaction of nolatrexed with
paclitaxel was observed. Typical pharmacokinetic parameters for
paclitaxel when administered as a single agent (Keung et al, 1993;
Gianni et al, 1995) are shown in Table 2. Patients on schedule 2
had a lower clearance of paclitaxel (165–238 ml min–1 m–2) when
compared to patients on the other 2 schedules (322–520 ml min–1
m–2), with the exception of patient 8. The paclitaxel clearance on
schedule 2 was comparable to that observed with a single-agent
dose of 175 mg m–2 and, as a result of the lower clearance on
schedule 2, peak plasma concentrations (1.66–1.93 mM versus
0.86–1.32 mM) and AUCs (392–565 mM min–1 versus 180–291 mM
min–1) were higher. The AUC achieved with 80 mg m–2 paclitaxel
on schedule 2 approaches that with a single-agent dose of 135 mg
m–2. The exception to the above generalizations was patient 8 who,
although treated on schedule 3, had pharmacokinetic parameters
similar to patients on schedule 2. This patient subsequently
received single-agent paclitaxel (135 mg m–2 as a 3-h infusion)
and, in the absence of nolatrexed, impaired elimination of
paclitaxel was still observed (CI = 127 ml min–1 m–2).
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Figure 1 In vitro growth inhibition studies with nolatrexed and paclitaxel
combinations for the HNX14C cell line. Graphs of log combination index (CI)
versus fraction of cells affected (Fa). Schedules 1 and 2 in (A) and schedule
3 in (B). The data points represent the mean value and standard deviation for
a minimum of three experiments. A CI value = 1 implies an additive effect of
the drug combination at that particular Fa. A value > 1 implies antagonism
and < 1 synergism
0.1
10.0
100.0
0.00 0.25 0.50 0.75 1.00
Fa
L
o
g
 
C
l
HNX22B
Sched 1 day 6
Sched 2 day 6
Sched 2 day 8
0.1
1.0
10.0
100.0
0.00 0.25 0.50 0.75 1.00
Fa
L
o
g
 
C
l
HNX22B
Sched 3 day 6
Sched 3 day 8
Sched 3 day 10
A
B
1.0
Figure 2 In vitro growth inhibition studies with nolatrexed and paclitaxel
combinations for the HNX22B cell line. Graphs of log combination index (CI)
versus fraction of cells affected (Fa). Schedules 1 and 2 in (A) and schedule
3 in (B). See Figure 1 for interpretationPaclitaxel metabolite peaks were identified by retention time
(Huizing et al, 1993) and peak concentrations and AUCs were
calculated. Paclitaxel metabolite AUCs were lowest in the
patients treated on schedule 2. Patient 8, on schedule 3, had 
high levels of both metabolites, both when paclitaxel was admin-
istered alone and in combination with nolatrexed, suggesting 
a deficiency in secondary metabolism or biliary elimination 
of paclitaxel.
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Figure 3 Plasma drug concentration versus time profiles for both paclitaxel and nolatrexed in a typical patient for each schedule of drug administration. Upper
panel schedule 1, middle panel schedule 2, lower panel schedule 3In vitro metabolism studies
Nolatrexed inhibited the metabolism of paclitaxel to its 6-hydroxy-
metabolite with a Ki of 0.64mM. In addition, nolatrexed inhibited
the metabolism of the model CYP3A4 substrate testosterone, with
a Ki of 2.7mM.
Toxicity
The toxicities experienced by the patients on all 22 courses of
therapy are summarized in Table 4. Only two courses were
complicated by myelosuppression. Patient 8 had grade 4 neutro-
penia, grade 3 leucopenia and grade 2 thrombocytopenia on her
only course of treatment. She had metastatic breast carcinoma and
had previously been treated with six cycles of epirubicin and
cyclophosphamide. As shown in Table 3, it is highly likely that the
toxicity can be explained by the pharmacokinetics of paclitaxel in
this patient. Patient 10 suffered grade 3 neutropenia with his only
course of treatment, although this did not require medical inter-
vention. He had metastatic caecal carcinoma and had previously
received 5-fluorouracil and folinic acid chemotherapy. Again, this
toxicity appeared to be related to the pharmacokinetics of pacli-
taxel as this patient was treated on schedule 2.
From the viewpoint of gastrointestinal side-effects, nine of 22
courses were complicated by toxicity of grade 3 or greater. Patient
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Table 2   The pharmacokinetics of paclitaxel and its metabolites given at a dose of 80mg m –2 in combination with nolatrexed
Paclitaxel 6-OH metabolite 3¢phenyl-hydroxy
metabolite
Patient Schedule Dose Peak conc. AUC Clearance Half-life Peak conc. AUC Peak conc. AUC
no (mg) (mM)(mMmin–1) (ml min–1 m–2) (min) (mM)(mM min–1)(mM)(mMmin–1)
1 126 1.00 227 411 421 0.26 120 0.37 162
1 146 0.89 249 376 442 0.05 23 0.06 18
1 131 1.32 291 322 507 0.06 19 ND ND
2 114 1.93 565 165 413 0.02 11 ND ND
2 146 1.66 392 238 381 0.02 8 ND ND
2 148 1.76 547 171 416 0.01 3 ND ND
3 124 0.86 180 520 365 ND ND ND ND
3 143 0.91 187 500 505 0.05 8 0.02 11
3 121 2.97 606 155 381 0.42 193 0.16 102
N/A 205 5.06 1239 127 360 0.79 217 0.4 172
Gianni, 1995 135mg m–2 3.30 654 247
Keung, 1993 135mg m–2 2.50 564 295
*These results are for patient 8 treated with single-agent paclitaxel (dose 135mg m–2). See text for explanation. AUC = area under plasma concentration-time
curve. ND = metabolite peak not detected.
Table 3The pharmacokinetics of nolatrexed given at a dose of 500mg m–2 day–1 in combination with paclitaxel
Patient no. Schedule Total dose Peak conc. AUC Clearance Half-life
(mg) (mg ml–1) (mg ml–1 min–1) (ml min–1 m–2) (min)
3 1 3940 6.2 18 137 66
6 1 4575 6.9 39 64 113
9 1 4100 6.7 36 70 128
5 2 3575 6.4 34 73 118
7 2 4575 6.6 23 108 95
10 2 4625 5.0 28 91 154
2 3 3875 6.7 26 99 97
4 3 4225 8.5 38 62 132
8 3 3800 5.6 32 79 114
AUC = area under plasma concentration/time curve.
Table 4Toxicity of the combination of paclitaxel and nolatrexed.
Grade
Toxicity 1 2 3 4
WBC 1
Platelets 1
Neutrophils 1 1
Nausea 8 3 3
Vomiting 1 1 2
Diarrhoea 5 1
Mucositis 5 4 3
Neurosensory 6
Rash 2 4
Fatigue 1 15
Alopecia 2
Arthralgia 4 2
*Others 6 7 3
Data from all three schedules have been pooled. (Figures represent the
number of patient courses in which a particular grade of toxicity was
experienced.) *Other toxicities included facial flushing, altered taste,
dyspepsia, pruritus and myalgia.
3
6
9
5
7
10
2
4
8
*8
3
6
9
5
7
10
2
4
82 experienced grade 3 nausea and grade 4 vomiting and was taken
off study because of this. This patient required intravenous anti-
emetic therapy, but had experienced similar problems prior to
receiving any treatment. There was no obvious association
between the gastrointestinal toxicity and schedule of treatment.
A grade 2 rash was experienced in four patient courses and
grade 2 fatigue in the majority of courses. Interestingly, neither of
the two chemotherapy-naive patients experienced any toxicity
greater than grade 2. Between them, they received six of the 22
courses of treatment.
Efficacy
Of the nine patients entered on the study, only six were evaluable
for response, receiving a total of 19 courses of treatment. Three of
these patients had stable disease after a minimum of four courses.
The other three patients progressed whilst on treatment. No
responses were observed on the study.
DISCUSSION
The aim of this study was to determine the optimum schedule and
pharmacology of the combination of paclitaxel and nolatrexed in
the treatment of solid tumours, particularly head and neck cancer.
As well as potential interactions in terms of anti-tumour effect and
host toxicity, the potential for pharmacokinetic interactions must
also be considered.
The metabolism of paclitaxel has been widely studied in
humans. Hepatic metabolism by the cytochrome P450 (CYP)
system and biliary excretion play an important role in the removal
of paclitaxel from the plasma (Kearns, 1997). The two major
metabolites observed in humans are 6-hydroxy paclitaxel, whose
formation is mediated by CYP2C8 (Cresteil et al, 1994) and 3¢-
phenyl-p-hydroxy paclitaxel mediated by CYP3A4 (Cresteil et al,
1994; Sonnichsen et al, 1995). Cytochrome P450 inducers such as
phenytoin and phenobarbitone would be expected to increase the
metabolism of paclitaxel and this has been shown in studies using
human liver preparations (Harris et al, 1994) and in patients (Kuhn
et al, 1997). Cytochrome P450 inhibitors, such as ketoconazole
and fluconazole, have been shown to inhibit the metabolism of
paclitaxel in in vitro studies (Jamis-Dow et al, 1997). However, no
metabolic interactions have been reported with the drugs
commonly used in the paclitaxel pre-medication regime, notably
dexamethasone, cimetidine and chlorpheniramine (Jamis-Dow
et al, 1995; Schlichenmyer et al, 1995). Paclitaxel clearance is
reduced when administered with multi-drug resistance reversal
agents (Berg et al, 1995).
In the current study, patients on schedule 2 who received
paclitaxel concurrently with nolatrexed had a lower clearance of
paclitaxel with higher peak paclitaxel plasma concentrations and
AUCs. In vitro studies demonstrated that nolatrexed was a 
potent inhibitor of CYP2C8-mediated metabolism of paclitaxel 
(Ki 0.64 mM) and of CYP3A4 (Ki 2.70 mM) which catalyse the two
major routes of paclitaxel metabolism. Thus, nolatrexed appar-
ently reduces the elimination of paclitaxel by inhibiting CYP450-
mediated metabolism. There was no schedule-dependent effect
on nolatrexed pharmacokinetic profiles when combined with
paclitaxel.
On schedules 1 and 3, paclitaxel pharmacokinetics were in
accord with previous data. The greater clearance of paclitaxel
observed, compared to literature values at higher doses, is consis-
tent with the reported non-linearity in paclitaxel pharmacokinetics.
The exception to this was patient 8, who was suffering from breast
carcinoma that had metastasized to the liver and bones. Liver func-
tion tests showed a bilirubin of 13 (normal range up to 18), alka-
line phosphatase of 638 (normal up to 120), AST of 87 (0–40) and
ALT of 116 (0–40). Hepatic metabolism and biliary excretion are
the main elimination pathways of paclitaxel in humans, and
paclitaxel metabolism is known to be impaired in patients with
decreased hepatic function (Wilson et al, 1994; Panday et al, 1997;
Chao et al, 1998; Venook et al, 1998). There is growing evidence
that dose reductions of paclitaxel should be routinely performed in
patients with altered hepatic function in order to avoid excessive
toxicity (Panday et al, 1997; Venook et al, 1998). After administra-
tion of single-agent paclitaxel (135 mg m–2 given as a 3-h infusion)
to patient 8, impaired elimination was again observed, supporting
the lack of an interaction between nolatrexed and paclitaxel and
impaired hepatic function as the most likely explanation for the
reduced paclitaxel clearance.
In previous studies, schedule-dependent effects have been
observed in clinical trials involving paclitaxel. When cisplatin was
administered before paclitaxel, more severe neutropenia was
observed than if the reverse schedule was used. The greater toxi-
city appeared to be due to reduced clearance of paclitaxel when it
was given after cisplatin, an effect that was attributed to the modu-
latory effect of cisplatin on cytochrome P450 enzymes (Rowinsky
et al, 1991). Conversely, myelosuppression has been shown to be
more severe when paclitaxel precedes cyclophosphamide adminis-
tered in combination (Kennedy et al, 1998), and it has been
reported that paclitaxel reduces doxorubicin elimination (Gianni
et al, 1997). Previous work has stressed the importance of the time
spent above certain critical plasma paclitaxel concentrations,
particularly in relation to predicting myelosuppression. The
threshold concentration has been reported to be either 0.1
(Sonnichsen and Relling, 1994) or 0.05 mM (Vigano et al, 1995).
Non-haematological (e.g. neuropathy) toxicities also relate more
closely to paclitaxel AUC and time spent above critical plasma
concentrations than with the administered dose. In the current
study, times above 0.1 mM were longer for schedule 2 (10–18 h)
compared to schedules 1 and 3 (5–8 h), and for times above 
0.05 mM a similar difference was seen (16–27 h compared to
8–18 h).
The in vitro combination studies demonstrated a potential
advantage for schedule 2, where a synergistic effect was observed
in at least one cell line. Conversely, for schedules 1 and 3, an
antagonistic profile dominated. Previous in vitro studies have also
shown schedule-dependent effects for paclitaxel in combination
with other chemotherapeutic agents. For example, in human
gastric and ovarian carcinoma cell lines, the combination of
cisplatin and paclitaxel was found to be either additive or even
synergistic when paclitaxel administration preceded that of
cisplatin by a 24-h period (Vanhoefer et al, 1995). Conversely,
when the drugs were co-administered or when cisplatin was given
before paclitaxel, strong antagonism was observed. Schedule-
dependency has also been examined using the combination of
paclitaxel and SN-38 (the active metabolite of irinotecan) and four
human cancer cell lines where additive effects were observed
regardless of the sequence of treatment (Kano et al, 1998).
However, simultaneous administration of the two drugs produced
antagonistic effects in three of the four cell lines. In vitro studies
with paclitaxel and 5-FU demonstrated antagonism when 5-FU
was administered prior to paclitaxel but more than additive cyto-
toxicity with the reverse schedule (Geoffroy et al, 1994).
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trexed and paclitaxel were studied, and all were well-tolerated.
Myelosuppression was rare with the major side-effect being
gastrointestinal toxicity. Fatigue was also common, affecting the
majority of patient courses. No responses were seen, although
three patients had stable disease.
In summary, the metabolism and hence clearance of paclitaxel is
impaired when the drug is co-administered with nolatrexed.
Further investigation of schedules and dosing was discontinued
because the combination of in vitro and in vivo data indicated that
the schedule most likely to be active produced a pharmacokinetic
interaction. Further exploration of this drug combination would
require careful dose optimization, especially given the non-linear
pharmacokinetics of both drugs.
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